メディロムADRの適時開示

6-K 1 mrm-20251009x6k.htm 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2025

Commission File Number 001-39809

MEDIROM HEALTHCARE TECHNOLOGIES INC.

(Translation of registrant’s name into English)

2-3-1 Daiba, Minato-ku

Tokyo 135-0091, Japan

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F On October 9, 2025, MEDIROM Healthcare Technologies Inc. (the “Company”) issued a press release relating to the Series A equity financing round of MEDIROM MOTHER Labs Inc., a subsidiary of the Company.

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

Issuance of Press Release

The information furnished in this report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, as amended, except to the extent specifically provided in such a filing.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press release of the Company

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MEDIROM HEALTHCARE TECHNOLOGIES INC.
Date: October 9, 2025
	By:	/s/ Fumitoshi Fujiwara
		Name: Fumitoshi Fujiwara
		Title: Chief Financial Officer

EX-99.1 2 mrm-20251009xex99d1.htm EX-99.1

Exhibit 99.1

【Series A Round Valuation: ¥9 Billion】

MEDIROM MOTHER Labs Inc. Decides to Make an Investment from Internal Investors

Tokyo, Japan – October 9, 2025: MEDIROM MOTHER Labs Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Yoshio Uekusa; hereinafter “MOTHER Labs”), a subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), today announced that it has approved a private placement of new shares to two officers, Yoshio Uekusa, President and CEO, and Ryo Saito, Director, as part of its Series A financing round, at a valuation of JPY9 billion. Funding is scheduled to occur by the end of October.

◼︎Background for Implementation

MOTHER Labs serves as the health tech division within the Medilom Group, having previously implemented specific health guidance programs using the healthcare app “Lav” and promoted the development and sales of wearable devices. To accelerate further business expansion, we determined that strengthening rapid decision-making and a management structure rooted in the field is essential. Therefore, it was decided to conduct this capital increase with the management team itself becoming investors, aiming to further heighten business responsibility and growth motivation.

◼︎Future Outlook

Through this capital increase, MOTHER Labs will strengthen its capital base while advancing the development of an upgraded version of its wearable device, the MOTHER Bracelet, and establishing systems for bringing products to market.

As the Medilom Group, we will realize new value creation in the healthcare and wellness field and further drive business growth both domestically and internationally.

MEDIROM MOTHER Labs Inc.

President and CEO

Yoshio Uekusa

March 2014: Graduated from Keio University, Faculty of Economics

April 2014: Joined Riraku Co., Ltd. (now Medilom Co., Ltd.)

January 2017: CEO Assistant and New Graduate Recruitment Team, MEDIROM Healthcare Technologies Inc.

June 2019: General Manager, Recruitment Group, MEDIROM Healthcare Technologies Inc.

June 2022: General Manager, MOTHER Group, MEDIROM Healthcare Technologies Inc.

July 2023: Representative Director, MEDIROM MOTHER Labs Co., Ltd. (Current Position)

MEDIROM MOTHER Labs Inc.

Director

Ryo Saito

March 2014: Graduated from Hokkai Gakuen University, Faculty of Business Administration

April 2014: Joined Riraku Co., Ltd. (now Medilom Co., Ltd.)

January 2017: Appointed Manager, Operations Group

November 2018: Appointed General Manager, Product Development Group

July 2020: Appointed General Manager, Development Group

July 2021: Appointed Director, Joy Hands Wellness Co., Ltd.

July 2024: Transferred to MOTHER Group

June 2025: Appointed Director, MEDIROM MOTHER Labs Co., Ltd. (current position)

■ABOUT MEDIROM MOTHER Labs Inc.

A subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), focuses on the health- tech sector. The company’s core activities include the 'Specific Health Guidance Program' offered through the 'Lav' health application and development and sales of the 24/7 recharge-free MOTHER Bracelet smart tracker. By leveraging the features of the recharge-free MOTHER Bracelet, MOTHER Labs offers customizable health management solutions across diverse sectors, including caregiving, logistics, manufacturing, etc.

◼︎MEDIROM Healthcare Technologies Inc.

MEDIROM Healthcare Technologies Inc.

NASDAQ Symbol: MRM

Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan

Web: https://medirom.co.jp/en

■Forward-Looking Statements Regarding MEDIROM

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes.

These statements relate to future events or to MEDIROM’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM’s operations, results of operations, growth strategy and liquidity. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release include:

●MEDIROM’s ability to achieve its development goals for its business and execute and evolve its growth strategies, priorities and initiatives;

●changes in Japanese and global economic conditions and financial markets, including their effects on MEDIROM’s expansion in Japan and certain overseas markets;

●MEDIROM’s ability to achieve and sustain profitability in its Digital Preventative Healthcare Segment;

●the fluctuation of foreign exchange rates, which affects MEDIROM’s expenses and liabilities payable in foreign currencies;

●MEDIROM’s ability to maintain and enhance the value of its brands and to enforce and maintain its trademarks and protect its other intellectual property;

●MEDIROM’s ability to raise additional capital on acceptable terms or at all;

●MEDIROM’s level of indebtedness and potential restrictions on MEDIROM under MEDIROM’s debt instruments;

●changes in consumer preferences and MEDIROM’s competitive environment;

●MEDIROM’s ability to respond to natural disasters, such as earthquakes and tsunamis, and to global pandemics, such as COVID-19; and

●the regulatory environment in which MEDIROM operates.

More information on these risks and other potential factors that could affect MEDIROM’s business, reputation, results of operations, financial condition, and stock price is included in MEDIROM’s filings with the Securities and Exchange Commission (the “SEC”), including in the “Risk Factors” and “Operating and Financial Review and Prospects” sections of MEDIROM’s most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future.